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1. Introduction
Non-communicable diseases (NCD), also known as chronic diseases represent one of the most
serious health challenges of the 21st century. According to the World Health Organisation
(WHO), global mortality due to NCD is projected to reach 55 million of deaths in the next 20
years, with 25 million of death caused by cardiovascular diseases (CVD) [1-3]. This is drawing
a particular attention to the importance of intensifying research in the area aiming at fighting
CVD through prevention and treatment. In a recent report of the WHO, CVD already ac‐
counted for 48% of NCD deaths [1]. Additionally, hypertension has been estimated to be the
major risk factor for CVD morbidity and mortality, causing 51% of stroke deaths and 45% of
coronary heart diseases deaths [1, 3]. Furthermore, CVD is increasing in the low- and middle-
income with Sub-Saharan African countries recording the highest rate of hypertension [1-3].
It has been observed that these countries record an increase in the overall rate of hypertension
mainly because of severe financial constraints for its management and control [1, 4].
With the prevalence of hypertension in the world’s death rate, new approaches to investigate
the treatment and management of this disease are highly in demand in order to reduce the
overall rate of adult mortality from CVD. Quest for solutions has open doors to research in the
field of alternative and complementary medicine as an effective, safe, simple and inexpensive
strategy. Medicinal plants and fruits and vegetables are reputed for their excellent health-
enhancing bioactive micronutrients, their cost-effectiveness and their widespread bioavailabil‐
ity [5-9]. While some medicinal plants have been investigated in hypertension research, many
remain a mystery [5-9]. Therefore, the interest of this review is to summarize the findings of
recent studies on the potential cardioprotective effect of Parkia biglobosa, a locally available
medicinal West African plant that has been reported to display anti-inflammatory, antimicro‐
bial, antioxidant, anti-cancer and hypotensive activities in its diverse parts [10-14]. In this
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chapter, a brief explanatory overview of hypertension and its implication in CVD will be given
followed by a summary of potential ability of Parkia biglobosa to modulate health, especially
CVD.
2. Hypertension
Hypertension, also known as raised blood pressure (BP), is a chronic medical condition and a
slow progressive disease defined by a mean systolic BP (SBP) of at least 140 mm Hg and/or a
diastolic BP (DBP) of at least 90 mm Hg [4, 15- 16]. In the USA, the seventh report of the Joint
National Committee (JNC 7) on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure has classified measured BP into different schemes and introduced a new
classification referred to as “Prehypertension” [15]. Prehypertension was not defined as a
disease-state but represented BP measurements of individuals at high risk of developing
hypertension (Table 1). Hypertension has been classified into primary hypertension or
essential hypertension (EH) and secondary hypertension (SH). They have respectively
unknown and known aetiology.
JNC 7 category
Blood pressure (mm Hg)
SBP DBP
Normal lower than 120 lower than 80
Prehypertension 120 to 139 80 to 89
Hypertension 140 or higher 90 or higher
Stage 1 140 to 159 90 to 99
Stage 2 160 or higher 100 or higher
Table 1. JNC 7 Classification of blood pressure [4, 15]
Hypertension is a major public health problem responsible for 51% of stroke deaths and 45%
of coronary heart diseases deaths [1, 3]. It represents the leading global risk factor of mortali‐
ty, about 12.8% of global death [3] and is also reported to affects both man and woman [17].
Additionally, the prevalence of hypertension is reported to increase with body weight and
advancing age [2, 15-16, 18]. Conversely, hypertension in children has been reported, especial‐
ly, in overweight and obese children [19]. It has been observed that Black men and women have
the highest prevalence of total hypertension [15-16]. Furthermore, while the large proportion
of the population suffers from EH (90-95%), only 5-10% among the cases suffers from SH [20-24].
It has been reported that most individuals have an uncontrolled hypertension because the
disease is predominantly a “silent” disease which is asymptomatic [17]. Epidemiological studies
estimated that in the United States, one in five adult remains unaware of his diseased-state [16].
Nonetheless,  with the rise of campaign aimed at increasing hypertension awareness and
treatment, the prevalence of uncontrolled hypertension is declining in developed countries,
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when compared to developing countries  [16,  18].  Actually,  the low- and middle-income
countries, especially Sub-Saharan African countries record an increase in the overall rate of
hypertension mostly because of the severe financial constraints, limited set of health services,
low access to facilities and low level of awareness, control, treatment campaigns [4].
2.1. Aetiology of essential hypertension
The aetiology of EH remains a mystery. Even though, EH is the commonest form of hyper‐
tension (90% - 95% of all cases), the underlying defects triggering its onset are not known. This
explains the difficulty in finding a definite cure. It has been theoretically proposed (Mosaic
Theory of Dr Irvine Page) that the aetiology of EH is multifactorial with genetic, environmental,
anatomical, adaptive, neural, endocrine, humoral, haemodynamic risk factors and that those
different risk factors interlink together to cause hypertension [25-27]. Some of these risk factors
are described below:
2.1.1. Environmental risk factors
Various dietary habits and unhealthy lifestyle have also been identified to play a major role in
the pathogenesis of hypertension such as:
• Pollutants
• Use of tobacco,
• Chronic consumption of alcohol,
• Lack of weight maintenance (sport inactivity),
• Adoption of diets characterised by high intake of glucose, high intake of saturated fat and
cholesterol, high intake of salt (exceeding 5.8 grams daily) [6, 28].
The consequences of this adopted lifestyle give the rise to metabolic and physiological
alterations which mediate the pathogenesis of hypertension and promotes other deleterious
conditions such as hyperglycaemia (principal characteristic of diabetes) and hyperlipidaemia
(principal characteristic of obesity) [29].
2.1.2. Hereditary risk factors
Genetic factors are thought to play a prominent role in the development of essential hyper‐
tension, especially genetic abnormalities of the baroreceptor system. However, the genes for
hypertension have not yet been identified.
The baroreceptor system consists of nerves ending receptors sensitive to stretch, pulse rate and
pressure changes of the blood vessels [30]. They are present on the wall of large arteries such
as the aortic arch and the carotid sinus (Figure 1). They stand as the first line of neural control
system over blood pressure fluctuation and constitute a short term regulation of BP [31-33].
With a significant change in BP, baroreceptors transmit impulses to central nervous system
(CNS) to activate a “feedback” mechanism from autonomous nervous system called barorecep‐
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tor reflex or baroreflex. The baroreceptor autonomous reflex restores the BP to normal values
[30-33]. It has been reported that that lack of baroreflex sensitivity is associated with the presence
of a family history of hypertension [32, 34]. This shows that hypertension could be initiated
from specific hereditary genetic abnormalities involving baroreceptors sensitivity [32, 34].
In addition, hereditary genetic abnormalities of the neuroendocrine regulation of barorecep‐
tors have similarly been recognised as predictors of EH. For instance, studies have related
overexpression of Chromogranin A (Cg A) in plasma, adrenal medulla and sympathetic
neurons to essential hypertension in both clinical and experimental models [25, 35]. Similarly,
Cg A loci genetic polymorphism was related to hypertension [36]. Chromogranin A is a pro-
hormone stored and released with catecholamine (epinephrine, norepinephrine and dopa‐
mine) by exocytosis [37-38]. It is believed that Cg A influence sympathetic tone since it is a pro-
hormone for active peptides with regulatory properties, namely vasostatin, pancreastastin and
catestatin [37, 39]. Catestatin exhibits catecholamine release-inhibitory function and may
function as a vasodilator [40-41]. Decreased circulating level of catestatin has been related to
EH because it increases adrenergic pressor response by no longer exerting antagonism to
neuronal nicotinic acetylcholine receptor [40-41].
Several genetic factors can affect the renin-angiotensin-aldosterone system and indirectly
result in hereditary hypertension. For instance, deficient formation of kinin components
(proteins that act locally to induce vasodilatation) in the body may also lead to hypertension
and development of CVD. Renal kinin-kallikrein system helps to excrete excess sodium from
the biological system [42]. Therefore, a reduction in renal expression of kinin-kalllikrein system
can also be identified as a genetic factor for hypertension as a result of accumulation of sodium
in the body. Consequently, diminished urinary kallikrein (sub-group of serine protease)
excretion could represent a genetic marker of hereditary hypertension [42-43].
2.1.3. Haemodynamic, endocrine, neural, anatomical risk factors
The cardiovascular system ensures the supply of blood to all organs and tissues via distensible
blood vessels such as arteries, veins and capillaries of the circulatory system (peripheral and
pulmonary). Blood pressure represents the force with which the blood pushes against the wall
of the arteries. At physiological level, factors such as blood volume, cardiac output, diameter
of artery lumen, and elasticity of artery determine BP [44-45]. In addition, different systems
contribute to the short-term and long-term regulation of BP such as:
• The nervous system baroreceptor reflex [46].
• The humoral secretion of vasoconstrictors and vasodilators substances such as acetylcho‐
line, atropine [47].
• The kidneys regulation of BP via renal body fluid feedback, namely the renin-angiotensin-
aldosterone system and the pressure natriuresis [31, 43].
Therefore, any molecular and physiological dysfunction affecting the regulation of BP can be
associated with the pathogenesis of hypertension such as dysfunctions of the renin angiotensin
system (RAS), dysfunctions in electrolytes homeostasis, dysfunctions of the endocrine system
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and increased arterial resistance [25, 48]. For example, the renin angiotensin system (RAS) is
a central system involved in the regulation of BP and electrolytes homeostasis. Briefly, with a
decrease in BP, kidneys prorenin are converted into active renin. Active renin cleaves the
hepatic precursor protein angiotensinogen into the inactive angiotensin I (Ang I) [43, 49]. Then,
the angiotensin converting enzyme (ACE) hydrolyses two principal molecules. Firstly, ACE
cleaves the inactive Ang I to give active vasoconstrictor hormone Angiotensin II (Ang II).
Angiotensin II, not only increases BP by constricting blood vessels but also causes the adrenal
gland to release aldosterone, a hormone which increase BP through renal retention of sodium
and water (increase of blood volume) and decrease excretion of potassium [42-43, 49].
Secondly, ACE which is a kininase II interact with the kinin-kalllikrein system and inactivate
the vasodilator bradikinin by releasing pentapeptide Arg-Pro-Pro-gly-Pheo and tripeptide
Ser-Pro-Phe fragments [42]. Therefore, failure to regulate the activated RAS at different level
could lead to hypertension. Another example of system dysfunction involved the failure to
regulate the increased activity of norepinephrine [48].
2.2. Aetiology of secondary hypertension
The aetiology of SH has been often identified with an underlying illness which indirectly
increases BP. It has also been demonstrated that SH can emerge from drugs intake and health
conditions such as pregnancy [15, 20, 50-52] (Table 2). Therefore, the treatment of SH is
associated along with the treatment of the identified underlying factors.
Causes Examples
Renal diseases RENAL PARENCHYMAL DISEASES:
•Glomerulonephritis
•Polycystic kidney diseases
•Diabetic nephropathy
•Hydronephrosis
•Chronic kidney disease (CKD)
RENOVASCULAR DISEASES/RENAL ARTERY
STENOSIS
•Atherosclerotic renal artery diseases
•Fibromuscular dysplasia
•Renal artery embolism
•Arteriovenous malformation of the renal
artery
Vascular diseases •Coarctation of aorta
•Aortoarteritis
Endocrinal and metabolic
diseases
•Primary aldosteronism (Conn Syndrome),
•Primary sodium retention (Liddle’s Syndrome)
•Cushing syndrome
•Pheochromocytoma
Neurological diseases •Brain tumours
•Encephalitis
Drugs •Oral contraceptive pills
•Non-steroidal anti-inflammatory medications
•Drug Abuse (Cocaine, Alcohol)
Table 2. Causes of secondary hypertension [52]
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2.3. Molecular mechanisms involved in the pathogenesis of hypertension
Previous studies have shown the involvement of excessive reactive oxygen species (ROS) in
the pathophysiology of CVD [53-56]. At a molecular level, oxidative stress (Oxs) has been
identified to have major implication in the development of clinical and experimental hyper‐
tension [57-59]. It was demonstrated that chronic glutathione depletion induced severe
elevation of arterial BP [60]. The lack of endogenous antioxidant enzymes worsens oxidative
stress and can indirectly promote the risk of hypertension. For example, a recent research
supports the influence of genetic polymorphism of antioxidant enzymes in increasing the risk
of hypertension [61]. Likewise, [62] in Taiwan demonstrated that manganese superoxide
dismutase (MnSOD) polymorphism significantly increased the risk of hypertension.
Inflammation and lipid peroxidation are central to the development of multiple CVD and are
mediated by a variety of cell types including macrophages, lymphocytes, endothelial cells and
vascular smooth muscles cells [63-65]. The multiple cell types which participate in vascular
inflammation produce various pro- and anti-inflammatory cytokines and specific membrane
receptors allowing them to transmit their effects to the cells. Studies place a strong emphasis
on the role of oxidative stress in the pathophysiology of hypertension through promotion of
chronic inflammation [66]. In fact, the rise of Oxs in the vasculature decreased bioavailability
of nitric oxide (NO). This leads to endothelial dysfunction due to the loss of vasodilation of
blood vessels [58, 67-69]. In addition, oxidative stress coupled with hyperlipidaemia and
hypercholesterolemia in the vasculature gives rise to atherosclerosis by oxidation of lipids in
the vessels. Atherosclerosis is an inflammatory disease leading to increased arteriolar resist‐
ance and increased large artery stiffness and obstruction of blood vessels and subsequent
ischemia [70].
2.4. Consequences of hypertension
The continuous high pressure exerted on the arteries wall causes long term damages to both
blood vessels and organs. In fact, when hypertension is not timely acknowledged and
controlled, damages to organs can become severe and fatal [15, 51-52]. Numerous complica‐
tions resulting from hypertension are illustrated in Table 3.
2.5. Orthodox therapeutic approaches to managing/treating hypertension
Although,  no  definite  cure  has  been  found  to  treat  essential  hypertension,  many  ap‐
proaches have been used to manage and control its incidence; in particular lifestyle changes
and the use of  medications.  Lowering salt  and alcohol  intake,  lowering consumption of
saturated fats and cholesterol rich food and practising regular exercise are important steps
taken towards control of BP [17]. However, these steps are often associated with prescrip‐
tion  of  anti-hypertensive  medication.  Many types  of  anti-hypertensive  drugs  have  been
developed  over  the  years  such  as  diuretics,  ACE  inhibitors,  angiotensin  II  receptor-
blocker,  calcium channel  blockers,  alpha and beta blockers  [71-73].  Even though a wide
variety of anti-hypertensive drugs are effective to control and manage hypertension, they
are not without considerable side effects [74-75]. Additionally, the cost of medication is not
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always affordable for the majority of  the population,  especially in developing countries,
since  managing  hypertension  represents  a  lifelong  financial  investment.  Henceforth,
research is now turning to alternative and complementary medicine. Many reports support
the concept that natural or dietary supplementation can be used to develop effective, safe,
simple and inexpensive antihypertensive treatment [6, 28]. As a result, many researches are
currently directed towards a search for useful bioactive compounds in medicinal plants as
a new strategy for the treatment and management of hypertension [5, 8, 49, 76].
2.6. Alternative therapeutic approach to hypertension
Deeper exploration of phytochemicals found in medicinal plants is used as an approach to
discover potential prophylactic and therapeutic agents in cardio protection [7-9]. Medicinal
plants can be used to develop effective, safe, simple and inexpensive antihypertensive
treatment since they are reputed for their excellent health-enhancing bioactive micronutrients,
their cost-effectiveness and their widespread bioavailability [7, 77-78]. As a result, research is
currently directed towards discovering useful bioactive compounds in medicinal plants that
could be used as new strategies for treatment and management of hypertension [5, 8, 49, 76].
End Organ CVD Damages Complications/
Consequences
Heart
•Acute coronary syndrome,
•Ischaemic heart diseases
•Myocardial infarction,
•Atrial fibrillation,
•Arrhythmias,
•Coronary artery disease,
•Left ventricular hypertrophy leading to chronic heart failure
Sudden death
Brain
•Constant headaches
•Stroke
•Neurological damages (memory loss, dementia)
•Disability (paralysis)
Sudden death
Kidney
•Renovascular dysfunction,
•Chronic kidney failure,
•End stage renal diseases (ESDR)
Death
Eyes Hypertensive retinopathy Blindness
Vascular system
•Atherosclerosis
•Arterial resistance
•Aneurysm
•Embolus and thrombo-embolus
•All the above
Brain, heart, kidney,
eyes damages Death
Table 3. End organs damages related to hypertension
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3. Parkia biglobosa
3.1. Brief description
Parkia biglobosa, also called the African Locust Bean tree is a multipurpose tree indigenous to
the tropical regions of West Africa. Parkia biglobosa belongs to the family Mimosaceae (Legu‐
minosae - Mimosoideae) [79-evidences. Therefore, studies of the]. Parkia biglobosa is a wide-
spread savannah tree used for nutritional and medicinal purposes [7, 81, 71]. The matured tree
can grow up to 30 m in height with a crown large of low branches. The bark is thick and fissured
with a grey to brown colour. The leaves are alternate, dark green and bipinnate. The leaves
are about 8-30 mm x 1.5-8 mm in size with 13-60 pairs of leaflets held on a long rachis [82].
 
Figure 1. Parkia biglobosa [83]
The analysis of the phytochemicals present in Parkia biglobosa revealed the presence of alkaloid,
flavonoids, tannins, saponins, cardiac glycosides, sterols, resins and terpenes (Table 4) [80,
84-85].
3.2. Potential health benefits of Parkia biglobosa
For a long time, native populations of West Africa have been using different parts of Parkia
biglobosa to meet their nutritional and basic health care needs. In different countries, Parkia
biglobosa has been used as a multipurpose plant in the therapy of a variety of diseases including
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hypertension. A summary of traditional medicine practices from different West African
countries is illustrated in Table 5.
The fact that repetitive information was obtained from traditional healers and population from
diverse regions and countries indicated the need to scientifically authenticate these folkloric
evidence. Therefore, studies of the extracts of Parkia biglobosa have been conducted and
experimental and clinical data are now recognizing the health benefits attributed to Parkia
biglobosa in its diverse parts. Parkia biglobosa bark extracts have been identified to have
significant anti-inflammatory, analgesic, antibacterial and anti-helminthic activities. For
example, the analgesic and anti-inflammatory property of Parkia biglobosa bark extract in the
management of toothache has been demonstrated [102]. The anti-venom activity of the bark
extract against snake bites has also been reported [103]. In 2007, some clinical investigations
described the antibacterial properties of Parkia biglobosa bark and root extracts against
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Shigella
dysenteriae responsible for urinary tract and digestive system infections [84, 86, 104]. Addi‐
tionally, Parkia biglobosa stem bark has been attributed anti-microbial effects against Bacillus
subtilitis and was recommended as a natural preservative against pharmacological contami‐
nations [85]. Parkia biglobosa leaf extract were described to exhibit anti-plasmodial activity
against malaria [105]. Recently, antioxidant, anti-carcinogenic and anti-trypanosomic activities
of the plant have been acknowledged [78, 97, 106-107].
3.3. Potential benefits of Parkia biglobosa in the treatment of hypertension and CVD
Previous investigations have indicated the hypotensive potential of Parkia biglobosa extracts.
For example, it was reported that a methanolic seed extract decreased blood pressure in the
Plant Parkia biglobosa
REFERENCES
Extracts (W,P,C,M) Leaf extracts Bark extracts Root extracts
Bio
ac
tiv
e c
om
po
ne
nts
Saponins + + + [85, 86, 87]
Cardiac Glycosides + + + [85, 87]
Tannins + + + [85, 86, 87]
Flavonoids (Anthocyanins, flavonones,
coumarins, catechins) + + + [85, 86, 87]
Alkaloids - + + [85, 87]
Resins + + + [85]
Carbohydrates + + + [85]
Sterols and Terpenoids + + + [86, 87, 88]
Abbreviations: W: water, P: petroleum ester, C: Chloroform, M: Methanol, +: Present, - : Absent.
Table 4. Brief summary of the bioactive components in Parkia biglobosa
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rat [10], an aqueous bark extract decreased blood pressure in rabbits [12] a hydroalcoholic bark
extract of Parkia biglobosa caused vasorelaxation [13] and a methanolic leaf extract demonstrat‐
ed hypotensive activities [14]. Hypercholesterolemia and hypertriglyceridemia are known risk
Countries Used Parts Traditional medicine practice References
Benin All parts
Treatment of digestive system diseases (diarrhoea,
dysentery, abdominal pain)
Treatment of diseases of the cardiovascular system
Treatment of injuries and burns
Treatment of infectious diseases (shingles, malaria,
abscesses, yellow fever, scabies, measles, chicken-pox,
oedema, jaundice)
Treatment of paediatric pathologies
Treatment of symptoms and syndromes: malaise,
tiredness, headaches, hip pain, ache, rheumatism,
elephantiasis, onset of paralysis
[89]
Burkina Faso Fermented seeds,leaves, stem bark
Treatment of oral infections: Gingivitis, toothache,
sores (tongues and lips) [90]
Ghana Leaves, stem bark, rawfruit, fermented seed Treatment of malaria, stomach ache [77]
Ivory coast Stem bark Treatment of malaria [91]
Mali
Leaves Wound healing [92]
Leaves,
stem bark
Treatment of malaria, urinary tract infection and
internal wounds of pregnant women [93]
Stem bark Personal health, insect management [94]
Nigeria (North) LeavesStem bark
Treatment of inflammations
Treatment of diarrhoea
[95]
[96]
Nigeria
(South West)
Stem bark Treatment of trypanosomiasis, fever, ulcer, woundhealing [78, 97]
Roots Treatment of hypertension, infertility, stomach ache,sore eye, anti-poison [98, 99]
Leaves Treatment of stroke, leprosy, skin lesion, eyeinfections [99]
Nigeria
(South East) Stem bark Treatment of hypertension [7]
Togo RootsStem bark
Treatment of haemorrhoids, Diarrhoea
Cardioprotection
[100]
[101]
Table 5. West African folkloric use of Parkia biglobosa for the treatment of diseases
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factors associated with hypertension and CVD. The anti-hyperlipidaemia effect of the aqueous
and methanolic extracts of Parkia biglobosa has been described to reduce hypercholesterolemia
and hypertriglyceridemia in diabetic rats [11]. Therefore, Parkia biglobosa could offer protection
against the development of coronary heart diseases in diabetics [11]. Recently, another study
on the methanolic leaf extract of Parkia biglobosa also confirmed protection against doxoru‐
bicin-induced cardiotoxicity in rats [87]. In this study, scientists proposed that protection was
offered through the antioxidant content and anti-inflammatory properties of the plant extract.
Alternatively, it was proposed that protection against cardiotoxicity might have originated
from the potential synergistic interactions among the plant phytochemicals. In fact, Parkia
biglobosa has a rich composition of secondary metabolites which have been individually
reported to possess excellent cardiovascular properties, namely:
• saponins (a vast group of glycosides) recently known for providing cardioprotective effects
in experimental model [108],
• cardiac glycosides (group of steroidal glycosides) reported to act as cardiotonic agent [109],
• tannic acid (typical product containing hydrolysable tannins) known for its ability to reduce
serum cholesterol and triglycerides [110-111],
• triterpenoids such as lupeol known to display antioxidant, anti-hypercholesterolemic and
cardioprotective activities [112-113],
• catechins (flavan-3-ol compounds) reported to reduce atherosclerotic plaques formation in
animal models [114],
• epicatechins known to reduce the risk of stroke and heart failure [115-116].
Furthermore, it was also reported that a leaf extract of Parkia biglobosa is a strong inducer of
endothelium-dependent relaxations involving both NO and EDHF via a redox-sensitive
mechanism [117]. Moreover, it was suggested that procyanidins fraction of the leaf extract
exerted beneficial effects on the endothelial function by decreasing vascular tone and are the
major inducers of the vasorelaxation [117].
In conclusion, many experimental and ethnoparmacological studies gave credence to the
health enhancing-potential of Parkia biglobosa extracts in the treatment of disease conditions
such as high blood pressure and CVD. However, there is still an important shortage of scientific
evidence elucidating the exact mechanisms through which Parkia biglobosa extracts offer
protection against hypertension. Therefore, further studies are warranted in CVD diseased-
model in order to identify the main phytoconstituents involved in the hypotensive response.
The mechanisms of action through which the plant extract offer protection against cardiotox‐
icity and hypertension should also be investigated. Furthermore, the indigenous population
have not adopted standardised methods (the population continue to use uncontrolled dosages
and in most instances, preparations of Parkia biglobosa extracts are stored in inappropriate
conditions) on the medicinal use of the plant. Therefore, caution and care are still needed to
be applied on the folkloric use of Parkia biglobosa.
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